PTC Therapeutics (PTCT) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

PTC Therapeutics NASDAQ: PTCT expects to provide 2027 sales guidance for its oral phenylketonuria treatment Sephience in January, as executives seek to convince investors that the drug's strong first year of sales can be…

PTC Therapeutics (PTCT) is rated Hold, bordering on Sell, with fair value estimated at $52/share versus a $59.97 current price. Sephience's strong launch drives growth, but legacy product declines offset gains; Q4 and 20…

WARREN, N.J., Nov. 3, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that its Board of Directors has authorized a share repurchase program under which PTC may repurchase up to $500 million of…

WARREN, N.J., Nov. 2, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Jefferies Global Healthcare Conference Monday, Nov. 16 at 11 …

WARREN, N.J., Oct. 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 28, 2026, the company approved non-statutory stock options to purchase an aggregate of 9.620 shares of its co…

PTC Therapeutics, Inc. (PTCT) Q3 2026 Earnings Call Transcript…

PTC Therapeutics NASDAQ: PTCT reported third-quarter 2026 total revenue of $358 million, including $276 million in net product revenue, as sales of phenylketonuria treatment Sephience continued to expand in the United St…

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and t…

PTC Therapeutics (PTCT) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.2 per share a year ago.…

– Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – – Full-year 2026 expected total revenue increased to $1.29 to $1.32 billion, with full-year product revenue gui…

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) Director Michael Schmertzler sold 2,500 shares of the stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $59.61, for a tot…

WARREN, N.J., Oct. 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its third quarter 2026 financial results and provide a busi…

PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) VP Mark Boulding sold 435 shares of the company's stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $64.16, for a total t…

Precigen (NASDAQ: PGEN - Get Free Report) and PTC Therapeutics (NASDAQ: PTCT - Get Free Report) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the st…

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) shot up 4.7% during trading on Monday. The stock traded as high as $65.75 and last traded at $65.60. 659,183 shares were traded during mid-day trading, a …

WARREN, N.J., Sept. 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept.…

– Completion of BLA submission expected in Q4 2026 – WARREN, N.J., Sept. 21, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo T…

PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

Amundi grew its stake in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 171.7% during a recent quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The ins…

California State Teachers Retirement System raised its stake in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 7,806.7% during a recent quarter, according to the company in its most recent Form 13F filing with the Se…

WARREN, N.J., Aug. 27, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Wells Fargo 21st Annual Healthcare Conference Thursday, Sept.…

– 17 abstracts and presentations planned at SSIEM Symposium – – Real-world evidence demonstrates significant diet liberalization achieved with Sephience while maintaining target blood Phe levels – – Continued evidence of…

PTC Therapeutics offers a compelling risk-reward profile, with its valuation not fully reflecting the upside from Sephience and potential ST-920 approval. Sephience, PTCT's lead asset, has driven rapid revenue growth, ac…

PTC Therapeutics NASDAQ: PTCT plans to acquire the ST-920 Fabry disease gene therapy asset through a competitive bankruptcy auction, positioning the company to add a potential one-time treatment to its rare disease portf…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 25. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.
Quiet tape today.

